{"id":596,"date":"2022-01-12T19:44:31","date_gmt":"2022-01-12T19:44:31","guid":{"rendered":"https:\/\/medicalmarijuanainc.com\/?p=1013293"},"modified":"2022-01-12T19:44:31","modified_gmt":"2022-01-12T19:44:31","slug":"medical-marijuana-inc-subsidiary-kannaway-opens-new-office-and-warehouse-in-warsaw-poland","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2022\/01\/12\/medical-marijuana-inc-subsidiary-kannaway-opens-new-office-and-warehouse-in-warsaw-poland\/","title":{"rendered":"Medical Marijuana, Inc. Subsidiary Kannaway\u00ae Opens New Office and Warehouse in Warsaw, Poland"},"content":{"rendered":"
SAN DIEGO, Jan. 12, 2022 (GLOBE NEWSWIRE) — via\u00a0NewMediaWire<\/u><\/a>\u00a0—\u00a0Medical Marijuana, Inc.<\/a>\u00a0(OTC: MJNA) (the \u201cCompany\u201d), the first-ever publicly traded cannabis company in the United States that launched the world\u2019s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary\u00a0Kannaway\u00ae<\/a>\u00a0has opened a new office and warehouse in Warsaw, Poland.<\/p>\n The new 7,771 square foot warehouse is strategically positioned near the Warsaw airport and city center, making it easily accessible for employees and visitors. The facility allows Kannaway\u00ae to use the Polish Post, DPD, and UPS to ship its high-quality cannabidiol (CBD) products to more than 30 countries in Europe. The warehouse operations follow Hazard Analysis Critical Control Points (HACCP) and Good Hygiene Practice (GHP).<\/p>\n \u201cOur company introduced CBD to the European marketplace. This new facility will allow us to further our growth while also improving our service levels,\u201d said Kannaway\u00ae CEO Blake Schroeder. \u201cThis year is predicted to bring significant progress for positive cannabis legislative changes and we look forward to helping many countries that are establishing their cannabis and CBD markets by offering them safe, accurately-labeled products of the highest quality.\u201d<\/p>\n According to\u00a0Graphical Research<\/a>, the European CBD market size surpassed $1.9 billion in 2020 and is estimated to witness over 33.5% CAGR from 2021 to 2027.<\/p>\n To learn more about Kannaway\u00ae, please visit the Company online at\u00a0https:\/\/www.kannaway.com\/<\/a>.<\/p>\n About Kannaway\u00ae About Medical Marijuana, Inc. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at\u00a0OTCMarkets.com<\/a>\u00a0or by visiting\u00a0www.medicalmarijuanainc.com<\/a>. To see Medical Marijuana, Inc.’s corporate video,\u00a0click here<\/a>.<\/p>\n FORWARD-LOOKING DISCLAIMER FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE LEGAL DISCLOSURE
\n<\/strong>Kannaway\u00ae<\/a>\u00a0is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products. Kannaway\u00ae currently hosts weekly online sales meetings and conferences across the United States, offering unique insight and opportunity to sales professionals who are desirous of becoming successful leaders in the sale and marketing of hemp-based botanical products.<\/p>\n
\n<\/strong>We are a company of firsts\u00ae<\/a>. Medical Marijuana, Inc. (MJNA<\/a>) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by\u00a0Kannaway\u00ae<\/a>\u00a0and\u00a0HempMeds\u00ae<\/a>; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including\u00a0AXIM\u00ae Biotechnologies, Inc<\/a>.<\/a>\u00a0and\u00a0<\/a>Neuropathix<\/a>. Medical Marijuana, Inc. was named a top CBD producer by\u00a0CNBC<\/a>. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product\u00a0Real Scientific Hemp Oil<\/a>\u00a0has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.<\/p>\n
\n<\/strong>This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and\/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.<\/p>\n
\n<\/strong>These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.<\/p>\n
\n<\/strong>Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.<\/p>\n